Highly unusually, none of the hotline presentations at this year’s annual meeting of the European Society of Cardiology, to be held in Munich on August 25-29, concerns trials sponsored by medtech companies. But two academic studies might affect device makers’ fortunes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,